Report Options 

 

 

 

 

NGS Leaders 

Date published June 2011

 

Additional info Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances - Table of Contents

Author: Ken Rubenstein, PhD

Executive Summary v
Evolution of NGS technologies v
State of the art v
Systems and technologies on the horizon vii
Market dynamics viii

CHAPTER 1 
Introduction 1
1.1 Scope and contents of this report 2

CHAPTER 2
Evolution of NGS 3
2.1 Classical sequencing and early applications 3
2.2 The Human Genome Project 5
2.3 First-generation sequencing 6
2.4 The Omics Era and the search for gene-disease associations 7
2.5 Origins and early development of next-generation sequencers 7

CHAPTER 3
State of the Art 10
3.1 Technologies currently on, or very near, the market  10
 Illumina 10
 Life Technologies 12
 Complete Genomics 14
 Roche/454 Life Sciences 17
 Helicos BioSciences 19
 Pacific Biosciences 20
 Ion Torrent 25
3.2 Comparative performance of systems currently on the market or nearly so 25
3.3 Bioinformatics 27
3.4 Sample preparation 33

CHAPTER 4
Systems and Technologies on the Horizon 37
4.1 Corporate programs 37
 Illumina Avantome 37
 Oxford Nanopore Technologies 38
 Electronic Bio Sciences 40
 General Electric Global Research 43
 GnuBio 43
 BioNanomatrix 44
 Halcyon Molecular 44
 IBM 45
 Intelligent Bio-Systems 46
 Life Technologies Starlight  47
 LightSpeed Genomics 47
 NABsys 48
 NobleGen 49
 ZS Genetics 50
4.2 Academic contributions 51
 Graphene Nanopores 51
 Other nanopore work 52

CHAPTER 5
Market Dynamics 54
5.1 Competitive environment in the sequencing market through 2011 54
5.2 Possible scenario through 2012 56
5.3 Prospects for diagnostic applications of NGS  58
5.4 Deals and deal patterns 59
 Instrumentation 59
 Informatics  60
 Sample preparation  61
5.5 User survey results and discussion 63
 Identification of respondents 63
 Nature of NGS activities 64
 Informatics activities 65
 Sequencer attributes 66
5.6 Survey Results from a Recent Bio-IT World Survey 70

CHAPTER 6 
Conclusions and Trends 73
6.1 Sequencing—The Next Generation 73
6.2 Translational medicine aspects of NGS 77
 Sample handling 79
 Data handling 79

CHAPTER 7
Interview Transcripts 81
Geoffrey Barrall, Ph.D., President, Electronic BioSciences 81
Stephen Turner, Ph.D., Founder and CTO, Pacific Biosciences 85
Clifford Baron, Director Biology Product Marketing, Accelrys 89
Clifford Reid, Ph.D., Co-founder, President, CEO, and Chairman, Complete Genomics 94
Jeffery Schloss, Ph.D., Program Director, U.S. National Human Genome Research Institute 99
Todd Smith, CTO, Geospiza 103

References 109

About Cambridge Healthtech Institute 118